United States

Eisai Co Ltd (4523.T)

4523.T on Tokyo Stock Exchange

9:36pm EDT
Change (% chg)

¥150 (+1.42%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Chart for


Eisai Co., Ltd. is engaged in the research and development, manufacture, sale and import and export of pharmaceuticals. The Company's business segments include pharmaceutical segment and other segment. The pharmaceutical segment is engaged in the research, develop, manufacture and sale of pharmaceuticals for medical use, generic... (more)


Beta: 0.74
Market Cap(Mil.): ¥3,235,546.00
Shares Outstanding(Mil.): 296.57
Dividend: 80.00
Yield (%): 1.37


  4523.T Industry Sector
P/E (TTM): 57.52 29.75 32.14
EPS (TTM): 189.68 -- --
ROI: 7.58 13.18 12.83
ROE: 9.28 15.14 14.95

Nikkei rises to 2-week high on weak yen, pharmaceuticals

* Paper sector pushed up by brokerage's target price hike on co

Aug 24 2018

Nikkei rises as weak yen helps mood; Eisai soars

TOKYO, Aug 24 Japan's Nikkei rose on Friday as a weaker yen supported sentiment, with the pharmaceutical sector leading gains after a report that Eisai moved forward its mid-term profit goal by one year.

Aug 23 2018

Japan's Eisai sets price tag of about $17,000 on liver cancer drug (Aug. 16)

(This version of the August 16th story corrects to change drug price in headline, first bullet, paragraphs 1 and 3 after company corrects it to $16,970 from $15,970)

Aug 17 2018

CORRECTED-(OFFICIAL)-UPDATE 2-Japan's Eisai sets price tag of about $17,000 on liver cancer drug (Aug. 16)

* Wholesale price before discount is $16,970 for a 30-day supply

Aug 17 2018

Japan's Eisai gains U.S. approval for liver cancer treatment

Aug 16 The U.S. Food and Drug Administration on Thursday approved https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm617185.htm a therapy by Japan's Eisai Co Ltd for previously untreated patients with a common form of liver cancer.

Aug 16 2018

Eisai shares fall 18 pct after release of Alzheimer drug test details

TOKYO, July 26 Shares of Japanese drugmaker Eisai fell more than 18 percent on Thursday after the company and its partner Biogen Inc presented the details of their experimental drug on Alzheimer's disease. (Reporting by Hideyuki Sano; Editing by Stephen Coates)

Jul 25 2018

Biogen/Eisai Alzheimer's drug cut cognitive decline by 30 pct -study

CHICAGO, July 25 Biogen Inc and partner Eisai Co Ltd said patients with early-stage Alzheimer's disease treated with their experimental drug BAN2401 experienced 30 percent less cognitive decline than patients who got a placebo in a highly anticipated midstage trial.

Jul 25 2018

Biogen's Alzheimer's drug succeeds in mid-stage trial

July 5 Japanese drugmaker Eisai Co and Biogen Inc said on Thursday that the final analysis of a mid-stage trial of their Alzheimer's drug showed positive results for patients who received the highest dose.

Jul 05 2018

Earnings vs. Estimates